Relationship between Antidiabetic Treatment with QT Dispersion During Acute Coronary Syndromes in Type 2 Diabetes: Comparison between Patients Receiving Sulfonylureas and Insulin

Abstract

Patients with acute coronary syndromes (ACS) show prolongation of QT interval duration and its dispersion (QTd). Prolongation of QTd has been associated with inhomogeneity of ventricular recovery times and high arrhythmyogenic potential. Previous studies have shown that preservation of the ischaemic preconditioning is associated with shorter QTd. Sulfonylureas may inhibit cardiac ischaemic preconditioning. The effect, however, of the previous treatment with sulfonylureas on QTd in patients with ACS has not been studied so far. This cross-sectional study examined the effect of the previous antidiabetic treatment on QTd in patients with type 2 diabetes during ACS. A total of 150 patients with ACS (myocardial infarction: n = 120; unstable angina: n = 30) admitted to the coronary care unit of our hospital were studied. Three groups of patients were examined: patients without diabetes (n = 60); patients with type 2 diabetes treated with sulfonylureas alone or in combination with metformin (n = 50); and patients treated with insulin alone or in combination with metformin (n = 40). Standard 12-lead ECG recordings at admission to the coronary care unit were obtained. QT interval duration and QTd were measured using ECG analysis software. At admission, QTd was not different between diabetic and non-diabetic patients (72.1 ± 21.7 vs. 78.4 ± 21.3 msec, p = 0.13, respectively). Similarly, the values of the above interval were also not different between patients with type 2 diabetes treated with sulfonylureas and insulin (73.8 ± 23.9 vs. 70.1 ± 18.5 msec, p = 0.55, respectively). It is concluded that the previous treatment with either sulfonylureas or insulin does not affect QTd in patients with type 2 diabetes and ACS.

Key words

QT interval - QT dispersion - acute coronary syndromes - sulfonylureas - type 2 diabetes - myocardial infarction

References

• 1 Ashcroft F M, Gribble F M. ATP-sensitive K⁺ channels and insulin secretion: their role in health and disease.  Diabetologia. 1999;  42 903-919
• 2 Bazett H C. An analysis of the time relations of the electrocardiogram.  Heart. 1920;  7 353-370
• 3 Bednar M M, Harrigan E P, Anziano R J, Camm A J, Ruskin J N. The QT interval.  Prog Cardiovasc Dis. 2001;  43 (Suppl 1) 1-45
• 4 Engler R L, Yellon D M. Sulfonylurea K-ATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration.  Circulation. 1996;  94 2297-2301
• 5 Gross G J, Auchampach J A. Role of ATP dependent potassium channels in myocardial ischaemia.  Cardiovasc Res. 1992;  26 1011-1016
• 6 Jain H, Avasthi R. Correlation between dispersion of repolarization (QT dispersion) and ventricular ectopic beat frequency in patients with acute myocardial infarction: a marker for risk of arrhythmogenesis?.  Int J Cradiol. 2004;  93 69-73
• 7 Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker K H, Kiowski W, Amann F W, Gruber D, Harris S, Burger W. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.  Eur Heart J. 1999;  20 439-446
• 8 Lebovitz H E. Insulin secretagogues: old and new.  Diabetes Reviews. 1999;  7 140-153
• 9 Lee C Y. Gating mechanisms of ATP sensitive potassium channels: implication in reperfusion injury and preconditioning.  Cardiovasc Res. 1994;  28 729-734
• 10 Meier J J, Deifuss S, Klamann A, Schmiegel W, Nauck M A. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The Langendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).  Exp Clin Endocrinol Diabetes. 2003;  111 344-350
• 11 Meinert C L, Knatterud G L, Prout T E, Klimt C R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes.  Diabetes. 1970;  19 (Suppl) 789-830
• 12 Murry C E, Jennings R B, Reimer K A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.  Circulation. 1986;  74 1124-1136
• 13 Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai M Z. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.  Exp Clin Endocrinol Diabetes. 2002;  110 212-218
• 14 Okishige K, Yamashita K, Yoshinaga H, Azegami K, Satoh T, Goseki Y, Fujii S, Ohira H, Satake S. Electrophysiologic effects of ischemic preconditioning on QT dispersion during coronary angioplasty.  J Am Coll Cardiol. 1996;  28 70-73
• 15 Riveline J P, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.  Diabetes Metab. 2003;  29 207-222
• 16 Suzuki M, Nishizaki M, Arita M, Ashikaga T, Yamawake N, Kakuta T, Numano F, Hiraoka M. Increased QT dispersion in patients with vasospastic angina.  Circulation. 1998;  98 435-440
• 17 Vegh A, Papp J G. Haemodynamic and other effects of sulphonylurea drugs on the heart.  Diabet Res Clin Pract. 1996;  31 (Suppl 1) S43-S53
• 18 Zabel M, Klingenheben T, Franz M R, Hohnloser S H. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study.  Circulation. 1998;  97 2543-2550